10 December 2015 - Nucala (mepolizumab) has been approved in Canada as add-on maintenance treatment of adult patients with uncontrolled severe eosinophilic asthma.

For more details, go to: http://ca.gsk.com/en-ca/media/press-releases/2015/gsk-receives-approval-for-nucala-mepolizumab-in-canada-for-the-treatment-of-severe-eosinophilic-asthma/